Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BeiGene, Ltd.
  6. News
  7. Summary
    BGNE   US07725L1026

BEIGENE, LTD.

(BGNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

BeiGene, Ltd. Closes on Property for New U.S. Manufacturing and Clinical R&D Center

11/23/2021 | 05:47pm EST

BeiGene, Ltd. has purchased a 42-acre site at the Princeton West Innovation Campus in Hopewell, N.J. to house a new state-of-the-art manufacturing campus and clinical R&D center. As a key part of company's continued growth, the company is investing in U.S. manufacturing to further expand and diversify its global supply chain and build new manufacturing capabilities for its deep pipeline of biologic and drug candidates. Subject to finalizing the development plans, BeiGene expects to invest several hundred million dollars in the initial phase of construction, in addition to the acquisition of the property, for the state-of-the-art facility that is expected to include up to approximately 400,000 square feet of dedicated commercial-stage biologic pharmaceutical manufacturing, including up to 16,000 liters of biologics capacity, along with clinical R&D and office space. Construction of the initial phase is expected to commence in 2022 and be completed in late-2023 or in 2024. In addition, the property has more than one million square feet of developable real estate for potential future expansion.


ę S&P Capital IQ 2021
All news about BEIGENE, LTD.
01/21BeiGene Announces Acceptance of a Supplemental New Drug Application in China for BRUKIN..
AQ
01/20Health Care Stocks Higher Ahead of Thursday's Close
MT
01/20BeiGene Says China's Medical Products Regulator Accepts Supplemental NDA for Blood Cell..
MT
01/20BeiGene Announces Acceptance of a Supplemental New Drug Application in China for BRUKIN..
BU
01/20BeiGene Announces Acceptance of a Supplemental New Drug Application in China for BRUKIN..
CI
01/19Leap Therapeutics Shares Rise Premarket on Encouraging Study Data
DJ
01/18Morgan Stanley Adjusts BeiGene's Price Target to $360 from $407, Keeps Overweight Ratin..
MT
01/10BEIGENE : China NMPA Approves Tislelizumab as Second- or Third-Line Treatment for Patients..
PU
01/10BEIGENE, LTD. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ..
AQ
01/07BeiGene - China NMPA Approves Tislelizumab as Second or Third-Line Treatment for Patien..
AQ
More news
Analyst Recommendations on BEIGENE, LTD.
More recommendations
Financials (USD)
Sales 2021 1 199 M - -
Net income 2021 -1 196 M - -
Net cash 2021 3 536 M - -
P/E ratio 2021 -22,1x
Yield 2021 -
Capitalization 25 835 M 25 835 M -
EV / Sales 2021 18,6x
EV / Sales 2022 15,5x
Nbr of Employees 7 600
Free-Float 67,7%
Chart BEIGENE, LTD.
Duration : Period :
BeiGene, Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BEIGENE, LTD.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 16
Last Close Price 251,45 $
Average target price 388,81 $
Spread / Average Target 54,6%
EPS Revisions
Managers and Directors
John V. Oyler Director
Xiao Bin Wu President & Chief Operating Officer
Julia Wang Chief Financial & Accounting Officer
Jane E. Huang Chief Medical Officer-Hematology
Lai Wang Global Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
BEIGENE, LTD.-7.19%25 835
GILEAD SCIENCES, INC.-5.65%85 938
REGENERON PHARMACEUTICALS-2.71%64 971
VERTEX PHARMACEUTICALS3.86%57 990
WUXI APPTEC CO., LTD.-9.18%49 645
BIONTECH SE-42.79%35 624